Status:

UNKNOWN

LIWA for Treatment of Alzheimer Patients

Lead Sponsor:

American Society Of Thermalism And Climatology Inc

Conditions:

Alzheimer Disease

Eligibility:

All Genders

50-80 years

Phase:

PHASE1

PHASE2

Brief Summary

The thermal therapy combined with magnetic fields and ozone has a direct effect on patients with dementia and Alzheimer's with a regression of more than 60% of them

Detailed Description

Alzheimer's disease (AD) is the leading cause of dementia and cognitive deteriorating in the advanced age. This main target of this study is to determine the safety and efficacy of transcranial magnet...

Eligibility Criteria

Inclusion

  • Men and women aged 50-85.
  • Diagnosed with Alzheimer's disease for at least half a year (by the DSM-IV criteria).
  • Scored 16-26 on the MMSE.
  • Received drug therapy for their disease, with each treatment having been administered at an acceptable dosage for at least 5 weeks.
  • Existence of a routine therapist for changes or adverse effects reports.
  • Existence of Alzheimer diagnosis by CT or MRI tests.
  • Answered in the negative to all questions in the pre-TMS treatment safety questionnaire.
  • Gave their oral and written consent to participate in the trial.

Exclusion

  • An additional neurological disorder.
  • Severe psychiatric disorder.
  • Uncontrolled hypertension, beyond 170/110.
  • History of epilepsy, seizure, or heat convulsion or History of epilepsy or seizure in first degree relatives.
  • History of head injury or stroke.
  • History of metal implants in the head (except dental fillings)or History of surgery entailing metallic implants or known history of any metallic particles in the eye, implanted cardiac pacemaker, cochlear implants, use of neuro stimulators, or any medical pumps.
  • History of migraines in the last six months.
  • History of drug or alcohol abuse.
  • Inadequate communication with examiner.
  • Participation in another clinical study, either concurrent with this trial or in the 3 months preceding it.
  • Inability to sign a consent form.
  • Leukemia

Key Trial Info

Start Date :

January 1 2015

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2015

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT02204969

Start Date

January 1 2015

End Date

December 1 2015

Last Update

January 6 2015

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Gaviota Clinic

Newark, New Jersey, United States, 07105

LIWA for Treatment of Alzheimer Patients | DecenTrialz